Imaging Performance Assessment of 89Zirconium-labelled Girentuximab (89Zr-TLX250) PET-CT in Metastatic Triple Negative Breast Cancer Patients
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: Triple Negative Breast Cancer
Interventions: DRUG: 89Zr-TLX250 PET/CT
Sponsor: Institut Cancerologie de l'Ouest
Collaborators: Telix Pharmaceutical|SIRIC ILIAD